Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 2/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.30 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.30 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30285429 | 1.00 | RHEB (0.32) | RHEBNR1H2NR1H3DHODHGRIN2D | |
| SCHEMBL29336743 | 0.87 | GRIN2D (0.33) | NR1H2NR1H3GRIN2DGRIN3BGRIN1 | |
| SCHEMBL30285438 | 0.87 | GRIN2D (0.33) | NR1H2NR1H3GRIN2DGRIN3BGRIN1 | |
| SCHEMBL29336642 | 0.85 | NR1H3 (0.34) | RHEBNR1H2NR1H3DHODHGRIN2D | |
| SCHEMBL30285294 | 0.85 | NR1H3 (0.34) | RHEBNR1H2NR1H3DHODHGRIN2D | |
| SCHEMBL29336718 | 0.81 | RHEB (0.35) | RHEB | |
| SCHEMBL29336910 | 0.80 | BACE1 (0.33) | RHEBDHODHGRIN2DGRIN3BGRIN1 | |
| SCHEMBL30285713 | 0.80 | CHEK2 (0.37) | DHODH | |
| SCHEMBL29336631 | 0.80 | CHEK2 (0.37) | DHODH | |
| SCHEMBL29336719 | 0.79 | RHEB (0.35) | RHEB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239784-A1 | INDOLE COMPOUNDS AND METHODS OF USE | GENZYME CORPORATION | 2024-07-18 | — | — | US | disclosed |
| US-20240239784-A1 | INDOLE COMPOUNDS AND METHODS OF USE | GENZYME CORPORATION | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239784-A1 | INDOLE COMPOUNDS AND METHODS OF USE | CFTR, INMT, IDO1 | RHEB 3259/4885NR1H2 1753/4885NR1H3 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.